Amendment Tool

v1.6 06 December 2021

For office use

QC: No

Section 1: Project information

Short project title*:	MAPS-2
IRAS project ID* (or REC reference if no IRAS project ID is available):	290474
Sponsor amendment reference number*:	MA_12_23
Sponsor amendment date* (enter as DD/MM/YY):	07 March 2023
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	This amendment consists for three changes to the MAPS-2 trial. (1) The recruitment window has been extended, meaning patients can now be recruited within 24 hours (instead of within 9 hours), and the protocol has been amended to reflect this change. (2) The Trial Pharmacist has changed, and this has been updated in the protocol. (3) The correction of two typographical errors in the protocol have been reconciled: the CTA reference number has been amended on the front page, and the CRP units within the protocol amendment table have been amended from mg/ml to mg/L.

Project type (select):	**Specific study**			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	**Yes**		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	**NHS/HSC REC**			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a **modified amendment** (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		**No**	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	**Yes**		No	
EudraCT number*:	2021-003853-40			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWoW) pilot)?:	Yes		**No**	
Did the study receive Pharmacy Assurance?:	Yes		**No**	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		**No**	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		**No**	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		**No**	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	**Yes**		No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes		**No**	
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		**No**	
Did the study involve children OR does the amendment introduce this?:	Yes		**No**	
Did the study involve NHS/HSC organisations prior to this amendment?:	**Yes**		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		**No**	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	**Yes**	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	**Yes**	**Yes**	**Yes**	**Yes**
Which nations will have participating NHS/HSC organisations after this amendment?	**Yes**	**Yes**	**Yes**	**Yes**

Section 2: Summary of change(s)

What do you want to update?:	**Project information**
	New site/PI only

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1					
Area of change (select)*:	Study Design				
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Minor change unlikely to affect safety or scientific value of study				
Further information (free text - note that this field will adapt to the amount of text entered):	The recruitment window in the inclusion criteria has been extended to allow patients to be recruited into the trial within 24 hours, instead of the initial 9 hours. The protocol has been updated accordingly; no other trial documents needed to be updated. This change has recommended by the NIHR and has been approved by the MAPS-2 TSC chair. This change should allow for more patients to be enrolled in the trial, thus boosting recruitment.				
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*:		**Yes**	**Yes**	**Yes**	**Yes**
Will all participating NHS/HSC organisations be affected by this change, or only some? (**please note** that this answer may affect the categorisation for the change):		**All**		Some	
				Remove all changes below	

Change 2					
Area of change (select)*:	Researchers				
Specific change (select - only available when area of change is selected first)*:	Changes to the research team (other than CIs or PIs)				
Further information (free text - note that this field will adapt to the amount of text entered):	Maria Scott has replaced Sheila Hodgson as the MAPS-2 Trial Pharmacist. This change is reflected on the contacts and signatures pages within the protocol.				
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*:		**Yes**	**Yes**	**Yes**	**Yes**
Will all participating NHS/HSC organisations be affected by this change, or only some? (**please note** that this answer may affect the categorisation for the change):		**All**		Some	
				Remove all changes below	

Change 3					
Area of change (select)*:	Study Documents				
Specific change (select - only available when area of change is selected first)*:	Correction of typographical errors				
Further information (free text - note that this field will adapt to the amount of text entered):	Two typographical errors have been amended in the protocol: (1) - The CTA reference number has been corrected on the front page of the protocol (2021-003853-40 amended to 03057/ 0075 / 001-0001). (2) - The measurement units of CRP have been corrected from mg/ml to mg/L within the protocol amendment table.				
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*:		**Yes**	**Yes**	**Yes**	**Yes**
Will all participating NHS/HSC organisations be affected by this change, or only some? (**please note** that this answer may affect the categorisation for the change):		**All**		Some	
				Add another change	

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]:*	Angela Shone
Email address:*	sponsor@nottingham.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																	
	UK wide:						England and Wales:				Scotland:				Northern Ireland:			
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category:
Change 1:						(Y)				(Y)				(Y)				(Y)	A
Change 2:						N				N				N				N	N/A
Change 3:						N				N				N				N	N/A
Overall reviews for the amendment:																			
Full review:						N				N				N				N	
Notification only:						Y				Y				Y				Y	
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	A																		